From Covance CEO to short-lived LabCorp diagnostics lead, Ratliff lands at AMRI

AMRI Headquarters
AMRI headquarters (AMRI)

John Ratliff’s position has changed three times this fall, but now, much like the falling leaves, he looks to have settled.

The former chief at major CRO Covance (now owned by LabCorp), Ratliff was announced back in October amid a raft of changes that he would be leaving his former post and moving up to lead LabCorp Diagnostics.

But that new role lasted three full business days when, mysteriously, LabCorp announced Ratliff’s immediate departure, with no explanation except one line about taking up a new opportunity.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Now, we know what that is: He’s going back to contract research, taking up the chief job at CRO and CDMO Albany Molecular Research (AMRI). He takes over from Michael Mulhern, who moves upstairs to lead the board.

Being it was so short, AMRI makes no mention of Ratliff’s ultra-brief role as diagnostics lead for LabCorp. Unsurprisingly, nor did he: “I am excited to join AMRI and look forward to collaborating with a very talented group of professionals,” said Ratliff in a short statement.

RELATED: Kirchgraber promoted to Covance CEO as former chief takes the reins at LabCorp Diagnostics

“Together we will strengthen AMRI’s position as a market leader and strategic partner for pharmaceutical and biotech companies worldwide. Michael and his team have accomplished a great deal, and I look forward to leading AMRI through its next phase of growth.”

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.